The interims provided little in way of new updates and was more of a summary of te path taken to be a therapeutic focussed company. In itself that is no bad thing but we remain concerned about the cash requirements to settle the bond and not least fund the Phase 1 of FAP-EXd (exatecan) due to commence in Q1,26. There is a focus on cash management and post period, the agreement with Heights regarding the convertible bond has been amended with the deferral of two placings. There has also been a series of small placings to raise cash to settle the bond. Discussions regarding partnering are on-going but there are no visible signs of progress.
